Andrew Orth - Feb 28, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Commercial Officer
Signature
/s/ Andrew Orth
Stock symbol
KRYS
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 05:45 PM
Previous filing
Mar 1, 2022
Next filing
Jun 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KRYS Common Stock 100 Feb 28, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +20K $0.00 20K Feb 28, 2023 Common Stock 20K $81.91 Direct F1
transaction KRYS Performance Stock Units Award $0 +10K $0.00 10K Feb 28, 2023 Common Stock 10K Direct F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in four equal annual installments beginning on February 28, 2024.
F2 Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement.
F3 The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award.
F4 If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025).
F5 If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire.